Presbyopia – Market Access and Reimbursement Insights Report – 2025
Presbyopia Market Access and Reimbursement Insights
Thelansis’s “Presbyopia
Market Access and Reimbursement Insights Report – 2025″ provides
comprehensive payer insights on the current and evolving market access and
reimbursement environments for branded and emerging drugs in the indication.
Our team understands the criticality of payer research and insights generation,
as well as their importance during drug development, pre-market launch
strategy, and post-marketing activities.
Presbyopia
Overview
Presbyopia presents a widespread
challenge affecting over a billion individuals globally. In developing regions,
up to half of those aged 50 and above grapple with unmanaged presbyopia due to
limited awareness and access to affordable treatment. Even in developed
nations, the prevalence can reach as high as 34%. The definitions of presbyopia
vary considerably, prompting a proposed redefinition: “Presbyopia arises when
the natural age-related decline in the eye’s focusing ability reaches a point
where, despite optimal correction for distance vision, near vision clarity
fails to meet individual needs.” Various strategies exist for addressing
presbyopia. These include the use of separate optical aids like reading glasses
or the adoption of optical lenses with multiple focal points such as bifocal,
trifocal, or progressive addition spectacles.
Geography
coverage:
G8 (United
States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights
driven by surveys* and interviews with payers (e.g.,
pharmacy directors / medical directors from managed care organizations with
Medicare and/or Commercial plans in the United States). If required, primary
market research with physicians is also done to understand the impact of
reimbursement environment on treatment decisions for current and emerging
brands.
*Survey and
interview discussion guide are customized based on client requirements
Deliverables
format:
- PowerPoint presentation
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Key business
questions answered:
- Market access and reimbursement for
current therapies
- Coverage on
plans
- Market access
restrictions
- Rebates and
contracting
- Factors
influencing formulary access
- HEOR
requirements and influence, etc.
- Expected market access and
reimbursement for key emerging therapies
- Level of
awareness
- Anticipated
coverage on plans
- Factors that
would improve market access
- Pricing, etc.
- Impact on brand use
- Key factors
driving and limiting brand use
- Best and worst
performers on market access, etc.
- Evolving environment
- Payer
expectations from emerging therapies
- New policies and
their expected impact, etc.
- Advise to drug
manufacturers and developers
Read more: Presbyopia – Market Access and Reimbursement Insights
Report – 2025
Comments
Post a Comment